According to a recent LinkedIn post from Cagent Vascular Inc, clinicians at CHU Saint-Pierre have begun using the company’s Serration Remodeling Therapy in Belgium and Luxembourg. The post highlights collaboration among a multidisciplinary team and acknowledges support from partners, including UMC Sint-Pieter – CHU Saint-Pierre and physician advocate Lorenzo Patrone.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests growing geographic adoption of Cagent Vascular’s technology and a focus on more controlled, durable vessel remodeling to improve limb- and life-saving outcomes. For investors, this may indicate early traction in European markets, potential expansion of procedure volumes, and a strengthening of clinical relationships that could support future reimbursement, commercialization, and competitive positioning in the vascular therapy segment.